Intraocular Inflammation After Intravitreal Faricimab Injections: A Case Series
Clinical & Experimental Ophthalmology · 2026
DOI: 10.1111/ceo.70058 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical & Experimental Ophthalmology, 2026. Verfasst von Yunhua Loo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Singapore National Eye Centre, Singapore. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Uveitis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Background
Intraocular inflammation (IOI) is a rare but potentially sight‐threatening complication that can occur after intravitreal anti‐vascular endothelial growth factor (anti‐VEGF) injections. This adverse event has been under scrutiny in recent years due to an increased incidence, particularly with some of the newer anti‐VEGF agents, such as Brolucizumab. Faricimab is a new anti‐VEGF medication that has been approved by the United States Food and Drug Administration. As it is relatively new on the market, long‐term safety data is still being collected.
Methods
This is a retrospective case series of 8 eyes in 5 patients with IOI that occurred after faricimab intravitreal injections.
Results
All patients were diagnosed with significant uveitis with anterior vitreous involvement and 4 out of the 5 patients presented subacutely with high intraocular pressure while the remaining patient presented acutely within 4 days following IVT with normal intraocular pressure. The patients received, on average, 4.875 faricimab injections prior to development of IOI and the inflammation resolved in all patients following cessation of faricimab injections and initiation of oral and topical non‐steroidal anti‐inflammatory agents and topical steroids.
Conclusion
Non‐infectious hypertensive uveitis can occur subacutely after intravitreal faricimab injections. It is imperative that intraocular pressure is promptly managed to reduce the risk of permanent glaucomatous damage. As all our patients presented with anterior vitreous involvement, it is also practical that such cases of IOI are not mistaken for infectious exogenous endophthalmitis to avoid unnecessary treatment with intravitreal antibiotics and surgery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Singapore National Eye Centre, Singapore.
ORCID-Profile: Yunhua Loo
Zitieren
APA
Loo, Y., Lim, J., Chew, M. C. Y., Chan, A. S. Y., & Wiryasaputra, S. (2026). Intraocular Inflammation After Intravitreal Faricimab Injections: A Case Series. Clinical & Experimental Ophthalmology. https://doi.org/10.1111/ceo.70058
Vancouver
Loo Y, Lim J, Chew MCY, Chan ASY, Wiryasaputra S. Intraocular Inflammation After Intravitreal Faricimab Injections: A Case Series. Clinical & Experimental Ophthalmology. 2026. doi:10.1111/ceo.70058
BibTeX
@article{Loo2026,
author = {Loo, Yunhua and Lim, Joshua and Chew, Milton Cher Yong and Chan, Anita Sook Yee and Wiryasaputra, Shaan},
title = {Intraocular Inflammation After Intravitreal Faricimab Injections: A Case Series},
journal = {Clinical & Experimental Ophthalmology},
year = {2026},
doi = {10.1111/ceo.70058}
}
EUVIMED